Clifford Chance topped Mergermarket's half-year league table of legal advisers for Global M&A by value, advising on 102 deals worth £101,741m.
The Firm also topped the European (by value), France (by volume and value), UK (by value), Benelux (by value), Nordic region (by value), the Germanic region (by value) and China (by volume) tables.
Matthew Layton, global head of the Clifford Chance corporate practice, commented:
"We are absolutely delighted with this result. Clifford Chance has acted on six of the top 10 global deals by value this year, a real testament to the broad strength of our practice and its focus on complex, cross-border transactions. There is no doubt that the global M&A market is feeling the impact of the continuing uncertainty in Europe and the effects on the global economy, but our performance underlines that there are still deals to be done across all sectors and we are enjoying a strong share of the legal market."
Deal highlights for Clifford Chance's Corporate practice in 2012 include advising:
•Pfizer on the sale of its nutrition business to Nestlé for US$11.85 billion in cash
•The Royal Bank of Scotland Group plc on the sale of the RBS Aviation Capital business for US$7.3 billion
•International Power plc (IPR) in connection with the £6.4 billion recommended cash offer to be made by Electrabel S.A. (“EBL”), a wholly owned subsidiary of GDF SUEZ S.A., to acquire the ordinary share capital of IPR not already owned by GDF SUEZ
•Deutsche Bank on the agreement to dispose of its controlling interest in global generic pharmaceutical company, Actavis for approximately €4.25 billion
•Royal Dutch Shell on its bid of £1.2 billion for Africa-focused Cove Energy
•EDF and Edison in relation to the re-organisation of the equity investments in Edison and Edipower for €1.51 billion
•Metropolitan Light Company Limited, a company formed by CVC Funds, on its acquisition of Hong Kong Broadband Network (HKBN) and the IDD business from City Telecom (H.K.) Limited (CTI) for HK$5 billion (US$641 million)
•Montagu Private Equity on the sale of BSN medical to EQT VI for €1.8 billion.
0+
